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Background: Periostin levels are associated with airway eosinophilia and are suppressed by corticosteroid
treatment in asthma. This study sought to determine the relationship between serum and sputum periostin,
airway inflammatory phenotype and asthma control.
Methods: Adults with poorly-controlled asthma (n = 83) underwent a clinical assessment, sputum induction and
blood sampling. Dispersed sputum was used for a differential cell count and periostin assessment (ELISA). Serum
periostin was determined by the Elecsys® immunoassay.
Results: Periostin levels were significantly higher in serum (median (IQR) of 51.6 (41.8, 62.6) ng/mL) than in sputum
(1.1 (0.5, 2.0) ng/mL) (p < 0.001). Serum and sputum periostin were significantly higher in patients with eosinophilic
asthma (n = 37) compared with non-eosinophilic asthma. Both serum and sputum periostin levels were significantly
associated with proportion of sputum eosinophils (r = 0.422, p < 0.001 and r = 0.364, p = 0.005 respectively) but
were not associated with asthma control. In receiver operator characteristic curve analysis, the area under the
curve (AUC) for serum periostin (n = 83) was 0.679, p = 0.007. Peripheral blood eosinophils assessed in 67 matched
samples, had a numerically greater AUC of 0.820 compared with serum periostin, p = 0.086 for the detection of
eosinophilic asthma.
Conclusion: In poorly-controlled asthma, sputum and serum periostin levels are significantly related to sputum
eosinophil proportions while their ability to predict the presence of eosinophilic asthma is modest.
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Asthma is a chronic heterogeneous inflammatory dis-
order of the airways where approximately 50 % of adults
have eosinophilic airway inflammation which is referred
to as eosinophilic asthma. Sputum eosinophils are an
effective monitoring tool in asthma when used in thera-
peutic decision making and there is good evidence that
this approach can significantly reduce severe exacerba-
tions [1, 2]. The technical difficulties associated with
sputum collection and processing limit the use of this
management strategy in clinical practice. Alternative and* Correspondence: jodie.simpson@newcastle.edu.au
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management.
We have recently shown that blood eosinophil counts
are a suitable surrogate for sputum eosinophil propor-
tion in identifying patients with eosinophilic asthma, be-
ing simple and readily available and thus may provide a
suitable asthma management tool [3]. Similarly, reports
also show that serum periostin levels are associated with
airway eosinophilia in asthma [4]. In bronchial brush-
ings, periostin gene expression is upregulated in a subset
of patients in which it was associated with the expres-
sion of Th2 cytokines. These patients also had higher
blood and BAL eosinophil counts and were most re-
sponsive to inhaled corticosteroids (ICS) [5]. Periostin is
expressed by lung epithelial cells and fibroblasts and in-
vitro experiments show that periostin is secretedle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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ever little is known about the airway levels of periostin
and the relationships between airway periostin levels,
asthma inflammatory subtypes and asthma control.
This study sought to examine the ability of serum peri-
ostin to predict the presence of eosinophilic asthma and
to determine the relationship between airway and serum
periostin levels, inflammatory subtype and asthma con-
trol in a group of adults with poorly-controlled asthma.
Methods
Study participants
Eligible adults with asthma (n = 83) who were partici-
pants in a randomised controlled trial of macrolides in
asthma. The diagnosis of asthma was established using
the American Thoracic Society guidelines based upon
the presence of current episodic respiratory symptoms
(past 12 months), doctor-confirmed diagnosis and
evidence of variable airflow obstruction [8] (airway
hyperresponsiveness, bronchodilator response or diurnal
variation of peak expiratory flow). They also were pre-
scribed maintenance ICS treatment and remained
poorly-controlled with an Asthma Control Questionnaire
6 (ACQ6) score >0.7 [9]. Participants with an FEV1 <
40 % predicted, current smokers, ex-smokers who had
ceased smoking in the previous year and those with an
exacerbation or respiratory infection in the past four
weeks were excluded. Those with significant smoking-
related emphysema (ex-smokers >10 pack year history
and carbon monoxide transfer coefficient <70 % pre-
dicted) OR smoking history >10 pack years and exhaled
carbon monoxide >10 ppm were also excluded.
Participants underwent a clinical assessment, allergy
skin test, spirometry with bronchodilator response, spu-
tum induction and blood sampling in turn. All tests
were performed on the same day prior to the com-
mencement of study medication. Measurements were
carried out by observers blinded to other results.
Ethics, consent and permissions
Subjects gave written informed consent (Approval to the
protocol was provided by the following ethics commit-
tee’s: Sir Charles Gairdner Group Human Research
ethics committee (2008-147), Royal Adelaide Hospital
Human Research Ethics Committee (081108f), Hunter
New England Research Ethics Committee (08/11/19/
3.03), The Prince Charles Hospital Metro North Hospital
and Health Services (HREC/08/QPCH/4), Metro South
Health Service District Human Research Ethics Commit-
tee (HREC/09/QPAH/015).
Study design
This cross-sectional study characterised participants
during a single visit where symptoms, atopy, medicationuse and smoking status were assessed, and the spirom-
etry and sputum induction and blood collection were
undertaken. Sputum was processed for inflammatory cell
counts and sputum supernatant and serum were stored
for periostin analysis.
Sputum induction and analysis
Spirometry (CPFS/D™ USB Spirometer, BreezeSuite™
v7.1, MGC Diagnostics, Saint Paul, MN, USA) and in-
duced sputum were performed. Sputum was induced by
the inhalation of hypertonic saline (4.5 %) as described
by Gibson et al. [10]. Subjects received a mean nebuliza-
tion time of 13.7 min.
Sputum was processed as described [10]. Selected
sputum portions were dispersed by dithiothreitol (DTT)
(Merck Millipore, Darmstadt, Germany) and a total cell
count performed. Cytospins were prepared and stained
with May-Grünwald Giemsa. Cell counts were per-
formed on 400 non-squamous cells. Cell viability and
differential cell counts were recorded.
Asthma subtypes were defined by percentages of spu-
tum eosinophils and neutrophils (of total inflammatory
cells) and were classified as eosinophilic asthma if spu-
tum eosinophils were ≥3 % and sputum neutrophils were
<61 %, as previously defined [11].
Blood samples and periostin serum assessment
Venous blood samples were collected without anticoagu-
lant. Periostin levels in serum were measured using the
clinical trial version of the Elecsys® Periostin immuno-
assay (Roche Diagnostics, Penzberg, Germany) intended
for use on the cobas e 601 immunology analyzer, an au-
tomated electrochemiluminescence immunoassay based
on the sandwich principle [12]. Peripheral blood eosino-
phil counts were assessed in 67 participants which are
part of a previously published dataset [3].
Periostin sputum assessment
Periostin levels in sputum were measured using the
Genentech proprietary ELISA using the same antibody
pair as the Elecsys® assay [4]. The limit of detection of
the assay is 9.4 pg/mL.
Analysis
The results were expressed as mean ± SD for continuous
variables and median with interquartile range (IQR)
when data were not normally distributed. Categorical
data were reported using frequencies and percentages. A
Kruskal-Wallis test was performed in the different sub-
groups of subjects with asthma. Spearman’s rank correl-
ation coefficient was used to assess the associations
between non-parametric data. Results were reported as
significant when p < 0.05. The performance characteris-
tics of the periostin variables were examined by receiver
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concentrations which best defined eosinophilic asthma
based on the sputum cell count. Participants were
assigned to the high periostin group if their serum peri-
ostin levels were ≥50 ng/mL [13].
Results
Participants consisted of 83 adults with a mean age of
61 years who were predominantly atopic (73 %) and
poorly-controlled (mean ACQ6 1.83) on treatment
(Table 1). A sputum cell count was available for 82/83
participants to assign inflammatory phenotype. Thirty-
seven participants had eosinophilic asthma, defined as
sputum eosinophils ≥3 % and 45 had non-eosinophilic
asthma. Most participants with non-eosinophilic asthma
(n = 28) had a paucigranulocytic phenotype (34 %);
17 had neutrophilic phenotype (21 %) and five par-
ticipants had a mixed eosinophilic and neutrophilic
phenotype (6 %).
Periostin levels in serum and sputum
For all subjects, periostin levels were significantly higher
in serum (51.6 (41.8, 62.6) ng/mL) than in sputum (1.11
(0.5, 2.0) ng/mL) (p < 0.001).
Sputum periostin was assessed at three dilutions, 1 in
2, 1 in 10 and 1 in 50. A matrix effect (a direct or indir-
ect alternation or interference in the measurement of an
analyte) was observed on assay linearity with increased
concentrations of periostin measured when the sampleTable 1 Patient characteristics
Number 83
Age, mean (range) 61 (21–82)
Sex, male (%) 42 (51)
BMI, mean (SD) 30.0 (5.5)
Atopy, n (%) 61 (73)
Ex-smoker, n (%) 34 (41)
Pack years, median (q1,q3) 26 (2,40)
FEV1 % predicted, mean (SD) 72.2 (20.3)
FEV1/FVC, mean (SD) 0.66 (0.12)




ACQ6, mean (SD) 1.83 (0.82)
ICS dose μg, median (q1,q3) 1000 (800,2000)
Taking regular OCS, n (%) 3 (4)
Sputum eosinophils %, median (q1,q3) 2.1 (0.5,9.5)
Blood eosinophils, x109/mL, median (q1,q3), n = 67 0.23 (0.11, 0.40)
BMI body mass index, ACQ6 Asthma Control Questionnaire 6, ICS inhaled
corticosteroid dose (in CFC beclomethasone equivalents), OCS
oral corticosteroidswas more diluted (four representative results are shown
in Table 2). To control for this effect, sputum periostin
levels were analysed at a single dilution. Using the 1:2
dilution, sputum periostin was detectable in 65/83
(78 %) samples, where most samples (n = 59) had spu-
tum periostin concentrations within the assay dynamic
quantitative range. Six samples had periostin levels that
were beyond the maximum of quantitative range at 1:2
and 17 samples had levels that were below the detection
level. Alternately, using the 1:10 dilution, sputum
periostin was detectable in 35/83 (42 %) samples;
this is significantly fewer when compared with the
proportion of samples detected using the 1:2 dilution
(78 % vs. 42 % p = 0.045). Subsequent analysis of
sputum periostin was undertaken using the results
from the 1:2 dilution.
We observed a reduction in periostin concentration
assessed when periostin protein was diluted in a spu-
tolysin containing diluent (see Additional file 1 and
Additional file 2).
Periostin levels and sputum eosinophils
Sputum and serum periostin were significantly higher in
patients with eosinophilic asthma compared with non-
eosinophilic asthma (Fig. 1).
Both serum and sputum periostin levels were signifi-
cantly associated with sputum eosinophils (r = 0.422,
p = 0.0001 and r = 0.364, p = 0.005 respectively, Fig. 2).
In order to examine the utility of serum and sputum
periostin to predict the presence of eosinophilic asthma
(≥3 % sputum eosinophils) we generated ROC curves.
The area under the curve (AUC) for sputum periostin
was 0.754, p < 0.001, whereas for serum periostin the
AUC was 0.680, p = 0.005 (Fig. 3). The AUC did not im-
prove by using a 2 % sputum eosinophil cut-off point to
distinguish eosinophilic from non-eosinophilic asthma
(data not shown).
Peripheral blood eosinophil counts were available in
only 67 participants. We compared the ability of blood
eosinophils and serum periostin as a biomarker to
predict the presence of eosinophilic asthma in the same
67 samples. Peripheral blood eosinophils had a moreTable 2 Sputum periostin levels increased with increasing
dilution of sputum supernatant
Dilution
ID 1:2 1:10 1:50
24312 0.35 0.49 0.95
24327 ND 0.17 ND
24488 0.27 0.49 1.78
24586 0.47 0.36 1.21
Periostin results are shown as ng of periostin per mL of sputum supernatant
ND not detected
Fig. 1 Periostin levels in participants with non-eosinophilic asthma
(NEA, open squares) and eosinophilic asthma (EA, open circles)
assessed in 55 sputum samples (a) and 77 serum samples (b). The
data was analysed using STATA 11 software. The horizontal line
represents the median value for each group. A rank-sum test was
performed with significance indicated when p < 0.05
Fig. 2 Scatter plots showing the association between sputum (a)
and serum (b) periostin levels with sputum eosinophils. The data
was analysed using STATA 11 software. Spearman’s rank correlation
was used to assess the associations between sputum and serum
periostin levels. Results were reported as significant when p < 0.05
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0.704 for serum periostin, p = 0.086.
Associations with clinical and inflammatory cell profile
There was no association between mean asthma control
score (ACQ6) and either sputum or serum periostin
levels (r = 0.038 and r = −0.062, p > 0.05 respectively).
Similarly, there was no difference in ACQ6 in those with
high serum periostin (≥50 ng/mL) or low serum
periostin (<50 ng/mL) levels (median ACQ6 1.8 vs
1.7, p = 0.530). Both sputum and serum periostin were
significantly and inversely associated with body mass
index (BMI) (r = −0.368, p = 0.004 and r = −0.325, p =
0.003 respectively) but not associated with ICS dose,
smoking pack years, lung function or atopy. There
was no difference in sputum or serum periostin levels
in never smokers compared with ex-smokers (data
not shown). Using logistic regression there was no
improvement in the model to explain the presence of
eosinophilic asthma by the addition of BMI to serum
periostin levels.BMI and periostin
Given the negative association observed between perios-
tin levels and BMI we sought to determine if BMI im-
pacted on the ability of serum periostin to predict the
presence of eosinophilic asthma. The ability of serum
periostin to predict the presence of eosinophilic asthma
was not improved following correction for BMI, with a
corrected AUC of 0.681, which was not statistically
different to the uncorrected AUC of 0.680, p = 0.551.
Discussion
In this well-characterised cohort with poorly-controlled
asthma, periostin was detected in 78 % of sputum sam-
ples at a 1:2 dilution. While levels of periostin in induced
sputum were lower than those measured in serum, both
sputum and serum periostin levels were significantly as-
sociated with airway eosinophilia. Additionally, both
sputum and serum periostin levels were significantly
higher in patients with eosinophilic asthma compared
with non-eosinophilic asthma. Our data are supported
by similar correlations between serum periostin and
sputum eosinophils in other cohorts [4, 14].
Fig. 3 Receiver operating characteristic (ROC) curves. The area under the curve (AUC) for (a) serum periostin in 83 samples (b) sputum periostin
83 samples and (c) the comparison of serum periostin and blood eosinophils in the same 67 samples. The data was analysed using STATA 11
software. The performance characteristics of the periostin (a and b) and blood eosinophil (c) variables were examined by calculating AUC which
was considered statistically significant when p < 0.05
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pared to serum are the result of limitations in detecting
proteins in sputum supernatant samples processed with
sputolysin, differences in the assays utilised in the detec-
tion of periostin or a biological difference between the
sample types. The ELISA that was used for the assess-
ment of sputum periostin was validated for the measure-
ment of serum periostin, but not sputum and the matrix
effect observed could influence the lower levels reported.
Also, while both the serum and sputum assays use the
same antibody pair, they use different platforms and re-
agents, which may lead to differences in sensitivity.
Serum periostin was measured previously by Genentech
using both assay platforms in 195 severe asthma serum
samples and on average Elecsys® Periostin values were
2.03 times (+/- 0.01 s.e.) greater than those derived by
ELISA (unpublished data). Since the assays have not
been standardized against each other, the levels can not
directly be compared. However, assay differences alone
are unlikely to explain the 50-fold difference between
sputum and serum periostin levels observed in this study
and further investigation is required including an assess-
ment of the variation of periostin levels over time in
sputum.
There may also be a biological explanation for the ob-
served lower levels of periostin in sputum. It has been
shown that periostin is strongly expressed at the RNAlevel in epithelial cells but protein expression could not
be detected in these cells [6, 7]. However, periostin is
immunolocalized to the basement membrane immedi-
ately below the epithelial cells as well as mesenchymal
cells [7]. This discrepancy between RNA and protein ex-
pression has led to the postulation that periostin protein
is rapidly secreted by airway epithelial cells into the sub-
epithelial layer. In vitro tissue culture experiments using
an air/liquid interface, representing the airway lumen
and bronchial tissue respectively, support this hypoth-
esis, as periostin was abundantly present in the basal
medium, but could not be detected in the apical washes
[7]. It is therefore feasible that periostin may not be
present in high concentrations in the sputum super-
natant collected from the airway lumen. Alternately, the
low sputum periostin levels may represent plasma leak-
age or the presence of periostin in the sputum super-
natant may indicate a sub-group of patients who have a
specific alteration in the epithelial barrier in some way
or suggest a different cellular source of periostin in the
sputum samples.
The utility of identifying eosinophilic asthma is well
established with improved management and reduced ex-
acerbations as key outcomes [1, 15]. However, sputum
induction is not widely available and is unlikely to be
adopted into routine clinical practice. As such, there is
an unmet need for surrogate biomarkers to assist clinical
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cant correlation between both serum and sputum
periostin and the sputum eosinophil proportions, the
strength of the association was relatively modest such
that neither sputum nor serum periostin levels could
sufficiently predict the presence of an eosinophilic in-
flammatory subtype with AUC in the poor to fair range
[16]. We then compared blood eosinophils and serum
periostin levels as surrogates to identify patients with eo-
sinophilic asthma as identified by sputum eosinophils
≥3 %. In agreement with Wagener et al [17], we found
blood eosinophils were an accurate predictor of patients
with eosinophilic asthma (AUC 0.829) and serum perios-
tin did not adequately distinguish eosinophilic from
non-eosinophilic asthma in adults. Sputum periostin
similarly lacked the rigor to be an adequate biomarker
to detect eosinophilic asthma in adults with poorly-
controlled asthma being neither sensitive nor specific
and has the added disadvantage of not being easily ac-
cessible in clinical practice. In the BOBCAT study,
serum periostin measured using the ELISA platform was
found to be a sensitive but not specific marker of airway
eosinophilia and performed better than blood eosino-
phils at predicting the presence of airway eosinophilia as
defined by eosinophils in both sputum and tissue [4]. Of
course, all studies so far including the current study re-
ported here may be limited by the numbers of partici-
pants included with varying patient characteristics, levels
of treatment and severity of asthma, and larger studies
may provide more insight into the ability of serum peri-
ostin to predict the presence of eosinophilic asthma.
There are limited studies supporting the utility of peri-
ostin in the management of asthma. There is evidence
that periostin levels can indicate better treatment out-
comes in studies involving the IL-13 monoclonal anti-
body lebrikizumab or anti-IgE antobody omalizumab [8,
13, 18]. In these studies blood eosinophils and fractional
exhaled nitric oxide (FeNO) were also able to identify
people with greater benefit and future clinical studies
need to determine how each of these biomarkers will be
used in clinical practice. While periostin levels may not
be suitable as surrogate markers for detecting the pres-
ence of eosinophilic asthma, its biomarker utility may
lay in its ability to predict treatment response to anti-IL-
13 therapy [13, 19], although this has yet to be tested in
prospective studies.
Conclusions
In poorly-controlled asthma treated with inhaled corti-
costeroids, periostin levels are low in airway secretions,
but can be detected. Although sputum and serum peri-
ostin levels are significantly related to sputum eosinophil
proportions, their ability to predict eosinophilic asthma
in poorly-controlled asthma appears relatively modest.Consent for publication
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where their identity was remained confidential.
Availability of data and materials
The detailed method describing validation of periostin
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The dataset(s) supporting the conclusions of this art-
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and inflammatory phenotype data.
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FeNO: fractional exhaled nitric oxide; FEV1: forced expiratory volume in 1 s;
ICS: inhaled corticosteroids; IQR: interquartile range; ppm: parts per million;
Th2: T-helper 2 cells.
Competing interests
CH and JJ declare that they are employees of Genentech.
Authors’ demonstrate that the data presented for the publication does
not compromise anonymity or confidentiality or breach local data
protection laws.
The authors declare that they have no competing interests and that all the
parts presented in this manuscript have not been duplicated elsewhere.
Authors’ contributions
JLS conceived the study, participated in the design and coordination,
performed the statistical analysis and prepared the manuscript. IAY
participated in participant recruitment and assessment and sample
collection. JWU participated in participant recruitment and assessment and
sample collection. PNR participated in participant recruitment and
assessment and sample collection. SH participated in participant recruitment
and assessment and sample collection. ALJ participated in participant
recruitment and assessment and sample collection. CJ participated in
participant recruitment and assessment and sample collection. MJP
participated in participant recruitment and assessment and sample
collection. JJ carried out the periostin assessment of sputum samples and
the sputum validation. CH participated in the study design and coordination
of sample assessment and helped draft the manuscript. PGG participated in
the study design, participant recruitment and assessment and sample
collection. All authors read and approved the final manuscript.
Acknowledgements
The authors would like to acknowledge the The Asthma and Macrolides:
Azithromycin Efficacy and Safety (AMAZES) study who collected and
processed the sputum samples from the patients who participated in
this study.
Funding
The study was supported by our NHMRC project grant. The funding body
was not involved in the study design, collection, analysis, data interpretation
and manuscript writing.
Simpson et al. BMC Pulmonary Medicine  (2016) 16:67 Page 7 of 7Author details
1Department of Respiratory and Sleep Medicine, Hunter Medical Research
Institute, Level 2, West Wing, Lot 1 Kookaburra Circuit, New Lambton
Heights, NSW 2305, Australia. 2Priority Research Centre for Asthma and
Respiratory Disease, The University of Newcastle, Newcastle, NSW, Australia.
3School of Medicine, The University of Queensland, Brisbane, QLD, Australia.
4Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane,
QLD, Australia. 5Department of Respiratory Medicine, Princess Alexandra
Hospital, Brisbane, QLD, Australia. 6Department of Thoracic Medicine, Royal
Adelaide Hospital, Adelaide, SA, Australia. 7Lung Research Laboratory, Hanson
Institute, Adelaide, SA, Australia. 8Department of Pulmonary Physiology and
Sleep Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
9School of Medicine and Pharmacology, The University of Western Australia,
Crawley, WA, Australia. 10Respiratory Trials, The George Institute for Global
Health, Sydney, NSW, Australia. 11Australian School of Advanced Medicine,
Macquarie University, Sydney, NSW, Australia. 12Department of Thoracic
Medicine, Concord General Hospital, Concord, NSW, Australia. 13Genentech
Inc, South San Francisco, CA, USA. 14Woolcock Institute of Medical Research,
Glebe, NSW, Australia.
Received: 29 December 2015 Accepted: 21 April 2016
References
1. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P,
et al. Asthma exacerbations and sputum eosinophil counts: a randomised
controlled trial. Lancet. 2002;30:1715–21.
2. Jayaram L, Pizzichini MM, Cook RJ, Boulet LP, Lemiere C, Pizzichini E, et al.
Determining asthma treatment by monitoring sputum cell counts: effect on
exacerbations. Eur Resp J. 2006;27:483–94.
3. Zhang XY, Simpson JL, Powell H, Yang IA, Upham JW, Reynolds PN, et al.
Full blood count parameters for the detection of asthma inflammatory
phenotypes. Clin Exp Allergy. 2014;44(9):1137–45.
4. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, et al. Periostin
is a systemic biomarker of eosinophilic airway inflammation in asthmatic
patients. J Allergy Clin Immunol. 2012;130(3):647–54. e10.
5. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T-
helper type 2-driven inflammation defines major subphenotypes of asthma.
Am J Respir Crit Care Med. 2009;180(5):388–95.
6. Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S,
et al. Genome-wide profiling identifies epithelial cell genes associated with
asthma and with treatment response to corticosteroids. Proc Natl Acad Sci
U S A. 2007;104(40):15858–63.
7. Sidhu SS, Yuan S, Innes AL, Kerr S, Woodruff PG, Hou L, et al. Roles of
epithelial cell-derived periostin in TGF-beta activation, collagen
production, and collagen gel elasticity in asthma. Proc Natl Acad Sci
U S A. 2010;107(32):14170–5.
8. Scheerens H, Arron JR, Zheng Y, Putnam WS, Erickson RW, Choy DF, et al.
The effects of lebrikizumab in patients with mild asthma following whole
lung allergen challenge. Clin Exp Allergy. 2014;44(1):38–46.
9. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al.
An official American Thoracic Society/European Respiratory Society
statement: asthma control and exacerbations: standardizing endpoints for
clinical asthma trials and clinical practice. Am J Respir Crit Care Med.
2009;180(1):59–99.
10. Gibson PG, Wlodarczyk JW, Hensley MJ, Gleeson M, Henry RL, Cripps AR,
et al. Epidemiological association of airway inflammation with asthma
symptoms and airway hyperresponsiveness in childhood. Am J Resp Crit
Care Med. 1998;158:36–41.
11. Simpson JL, Phipps S, Baines KJ, Oreo KM, Gunawardhana L, Gibson PG.
Elevated expression of the NLRP3 inflammasome in neutrophilic asthma.
Eur Respir J. 2014;43:1067–76.
12. Sherman J, Holweg C, Kincaid H, Sidobre S, Ma L, Rigl T, et al. The elecsys
periostin assay as a companion diagnostic for the novel asthma drug
lebrikizumab. Clin Chem. 2014;60(10 suppl):S25–6.
13. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR,
et al. Lebrikizumab treatment in adults with asthma. N Engl J Med.
2011;365(12):1088–98.
14. Kim MA, Izuhara K, Ohta S, Ono J, Yoon MK, Ban GY, et al. Association of
serum periostin with aspirin-exacerbated respiratory disease. Ann Allergy
Asthma Immunol. 2014;113(3):314–20.15. Jayaram L, Pizzichini MM, Cook RJ. Determining asthma treatment by
monitoring sputum cell counts: effect on exacerbation. Eur Respir J.
2006;27:483–94.
16. Xia J, Broadhurst DI, Wilson M, Wishart DS. Translational biomarker discovery
in clinical metabolomics: an introductory tutorial. Metabolomics: Official
journal of the Metabolomic Society. 2013;9(2):280–99.
17. Wagener AH, de Nijs SB, Lutter R, Sousa AR, Weersink EJ, Bel EH, et al.
External validation of blood eosinophils, FENO and serum periostin as
surrogates for sputum eosinophils in asthma. Thorax. 2015;70(2):115–20.
18. Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, et al.
Exploring the effects of omalizumab in allergic asthma: an analysis
of biomarkers in the EXTRA study. Am J Respir Crit Care Med.
2013;187(8):804–11.
19. Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, et al.
Lebrikizumab in moderate-to-severe asthma: pooled data from two
randomised placebo-controlled studies. Thorax. 2015;70(8):748–56.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
